三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
SB-525受试者接受治疗后体内FVIII活性水平变化
SB-525受试者接受治疗后体内FVIII活性水平变化
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:161KB
图片尺寸:1207*779
同报告图片
/
4
所属报告:
医药生物行业生物药前沿研究系列之血友病专题:罕见病大市场-190816(47页).pdf
打包全文图表
相关数据
Ph3ORIGIN3研究中Atacicept及安慰剂组受试者第36周uPCR及Gd-IgA1数据
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
收藏
行业数据
2026-03-13
原图定位
查看详情
Ph1/2ADU-CL-19研究中Zigakibart组受试者100周uPCR及eGFR数据
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
收藏
行业数据
2026-03-13
原图定位
查看详情
点击查看详细解答详细解答样本量较小,应谨慎解读结果您对智的解答是否满意?无论Trop-2表达如何,mTNBC受试者中SG相比TPC的临床获益均得到证实。与接受TPC的受试者相比,在接受SG的受试者中,观察到Trop-2评分中等或高的受试者,有效性结局优于Trop-2评分低的受试者(表1)。由于只体内容和参考文献见详细解答如您需要最新版本,请点击医学问询索该问题详细解答的标准文件定期更新取 向询文献8 参考文献and animalmodeldata.Theyareforsusceptibilitytestingof yeastsInterpretivebreakpointsforsusceptibilitytakeintoaccounttheMIC,aswellaspharmacokinetic/pharmacodynamicdatareported foreachspeciesBreakpoints have beenestablishedformost,butnotalldrugsforthe5mostcommonCandidaspecies(Table1)回复内容摘自指南原文,翻译仅供参考,请结合实际临床情况进行综合判断2016,62(4):e1-50.P4Pappas PG,et al.Clin InfectDis 指南主页 M27-A3and theEuropeanCommitteesusceptibilitytakeinto account theand animalmodeldata.TheyarereportedforeachspeciesBreakpointshavebeen为您推荐以下相关内容Intensiveeffortstodevelopforfungihaveresultedinthedevelopmentof the ClinicalandLaboratory Standards Insti tute(CLSI)onAntimi crobial Susceptibilityforsusceptibility testing of yeastsInterpretivebreakpointsforMIC,aswellaspharmastandardized,rproducible,andevantsusceptibilitytestingmethodsTesting(EUCAST)methodologiescokinetic/pharmacodynamic dataestablishedformost,butnotall 问询民主页文献指南
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
收藏
行业数据
2026-01-19
原图定位
查看详情
韩国受试者注射丽珠兰黑盒后12周面部肤质皱纹改善明显
fCDml7bpl7TngrkgICAgICAgICB8IOWPs+S+p++8iFJ077yJIHwg5bem5L6n77yITHTvvIkgfAp8LS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tfAp8IOWfuue6v++8iEJhc2VsaW5l77yJfCDpnaLpg6jogqTotKjnmrHnurnnirbmgIEgfCDpnaLpg6jogqTotKjnmrHnurnnirbmgIEgfAp8IDEy5ZGo5ZCOICAgICAgICAgfCDmlLnlloTmmI7mmL4gICB8IOaUueWWhOaYjuaYviAgIHwKCui1hOaWmeadpea6kO+8mumSu+minOaJgOWFrOS8l+WPt++8jOS4nOaWuei0ouWvjOivgeWIuOeglOeptuaJgA==
收藏
行业数据
2025-12-09
原图定位
查看详情
图21.DC20在老年受试者单次给药后的主要药代动力学参数
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
收藏
行业数据
2025-08-05
原图定位
查看详情
图14.ZX2010二期临床试验设计(长效GLP-1/GIP双重受体激动剂(ZX2010)注射液在中国2型糖尿病受试者
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
收藏
行业数据
2025-08-05
原图定位
查看详情
图13.ZX2021二期临床试验设计(在非糖尿病的超重或肥胖受试者中评价ZX2021注射液的有效性、安全性及药
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
收藏
行业数据
2025-08-05
原图定位
查看详情
SPH3127与安慰剂相比可显著降低受试者血压
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
收藏
行业数据
2025-06-27
原图定位
查看详情
视力提高≥15个字母的受试者比例(假性白内障患者)
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
收藏
行业数据
2025-06-23
原图定位
查看详情
视力提高≥15个字母的受试者比例(有症状的受试者)
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
收藏
行业数据
2025-06-23
原图定位
查看详情
相比基线平均BCVA变化(有症状的受试者)
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
收藏
行业数据
2025-06-23
原图定位
查看详情
大多数受试者早在8至16周即实现免疫学完全缓解(ICR)
fCDml7bpl7QgICB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElDUu+8iSB8IOWFjeeWq+WtpuWujOWFqOe8k+ino++8iElD
收藏
行业数据
2025-06-09
原图定位
查看详情
大多数受试者早在8至16周即实现免疫学完全
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
收藏
行业数据
2025-05-26
原图定位
查看详情
表7、各年龄组受试者接种MCV4和对照组疫苗后0-30d局部和全身不良反应发生率
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
收藏
行业数据
2025-04-01
原图定位
查看详情
610和同类产品对重度哮喘受试者肺功能改善的比较(FEV1
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
收藏
行业数据
2025-03-31
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
SB-525是Sangamo Therapeutics, Inc.和辉瑞(Pfizer, Inc.)联合开发的重度血友病A基因治疗药品,2019年7月于第二十七届国际血栓和止血学会(ISTH)会议上公布了临床I/IIa期的最新研究结果:数据显示,SB-525总体耐受性良好,并且受试者的FVIII活性水平呈现剂量依赖性增加。此次临床试验一共入组10位患者,并将其分为4个剂量爬升组,9e11 vg/kg (2位患者),2e12 vg/kg (2位患者),1e13 vg/kg (2位患者)和3e13 vg/kg(4位患者)。
行业数据
原图定位
当前图表所属:
医药生物行业生物药前沿研究系列之血友病专题:罕见病大市场-190816(47页).pdf
国内人凝血因子Ⅷ在研情况
不同剂量的预防性治疗年均费用情况
2018年各省血友病用药医保报销上限情况
国内血友病用药纳入医保情况
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》